

CYH33 biochemical

CYH33

CATALOG #
AAA227755


PRODUCT SYNONYMS

CYH33; CYH33 biochemical

PRODUCT SPECIFICATIONS


Purity/Purification	98%
CAS	1494684-28-4
Targets&IC50	PI3Kgamma:225 nM (IC50), PI3Kalpha:5.9 nM (IC50), PI3Kbeta:598 nM (IC50), PI3Kdelta:78.7 nM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	CYH33 (2-20 mg/kg; oral; once a day for 21 days) potently restrains tumor growth in mice bearing human breast cancer cell xenografts[2]. Single administration of CYH33 (20/mg/kg; oral) significantly down-regulates the level of phosphorylated Akt in tumor tissues, demonstrating the suppression of PI3K signaling in nude mice[2]. CYH33 (10/mg/kg; oral; once a day for 18-d or 20-d respectively) delays the restoration of blood glucose and area under the curve (AUC) of blood glucose increased upon CYH33 treatment in T47D xenografts and R26-Pik3ca H1047R; MMTV-Cre mice[2]. Animal Model: SCID mice aged 4-6 weeks bearing human breast cancer T47D xenografts[2]. Dosage: 2, 5, 10, 20 mg/kg. Administration: Oral; once a day for 21 days. Result: Displayed marginal inhibitory effect on the tumor growth at lower doses (2 and 5mg/kg) and significantly attenuated tumor growth at the dose of 10 or 20mg/kg, yielding T/C values of 58.36% and 49.42% respectively.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure

Methyl 2,3-O-Isopropylidene-beta-L-ribofuranoside, CAS 20672-63-3



Structure

Methyl 2,3-O-Isopropylidene-beta-L-ribofuranoside, CAS 20672-63-3

ADDITIONAL INFORMATION

Related Product Information for CYH33 biochemical	CYH33 is an orally active, highly selective PI3Kalpha inhibitor with IC 50 s of 5.9 nM/598 nM/78.7 nM/225 nM against alpha/beta/delta/gamma isoform, respectively. CYH33 inhibits phosphorylation of Akt, ERK and induces significant G1 phase arrest in breast cancer cells and non-small cell lung cancer (NSCLC) cells. CYH33 has potent activity against solid tumors.
References	1. Jürgen Wagner, et al. Enantiomerically pure 7-oxabicyclo[2.2.1]hept-5-en-2-yl derivatives as synthetic intermediates. Part III. Total synthesis of D- and L-ribose derivatives.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://www.aaabiotech.com/biochemical/cyh33/227755>